68065-11-2

Usage

Uses

Used in Pharmaceutical Industry:
4-(3-Bromo-propoxy)-phenol is used as an intermediate for the synthesis of pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs.
Used in Agrochemical Industry:
In the agrochemical industry, 4-(3-Bromo-propoxy)-phenol is used as an intermediate in the production of various agrochemicals. Its properties make it suitable for use in the development of pesticides and other agricultural chemicals.
Used in Dye Industry:
4-(3-Bromo-propoxy)-phenol is also used as an intermediate in the dye industry. Its chemical structure contributes to the creation of new dyes with specific color properties.
Used in Organic Synthesis:
4-(3-Bromo-propoxy)-phenol serves as a reagent in organic synthesis. Its bromine atom and propoxy group make it a versatile building block for the preparation of other organic compounds.
Used in Research and Development:
Although not widely studied for biological or toxicological effects, 4-(3-Bromo-propoxy)-phenol is used in research and development to explore its potential applications and properties. Proper handling and personal protective equipment are essential when working with 4-(3-BROMO-PROPOXY)-PHENOL due to its potential hazards.

InChI:InChI=1/C9H11BrO2/c10-6-1-7-12-9-4-2-8(11)3-5-9/h2-5,11H,1,6-7H2

Upstream product

• 108534-47-0 4-(tert-butyldimethylsilyloxy)phenol 
• 123-31-9 hydroquinone 
• 109-64-8 1,3-dibromo-propane 
• 103-16-2 4-Benzyloxyphenol 
• 80199-92-4 1-benzyloxy-4-(3-bromopropoxy)benzene 

Downstream Products

• 1431659-37-8 4-(3-(ethyl(phenyl)amino)propoxy)phenol 
• 841200-73-5 1-[3-(4-hydroxy-phenoxy)-propyl]-4-phenyl-piperidin-4-ol hydrogen bromide 
• 910032-57-4 [4-(3-bromo-propoxy)-phenoxy]-acetic acid methyl ester 

Relevant academic research and scientific papers

Ionic-liquid supported rapid synthesis of an: N -glycan core pentasaccharide on a 10 g scale

A new and efficient Ionic Liquid-Supported Oligosaccharide Synthesis (ILSOS) strategy for an N-linked core pentasaccharide on a 10 g scale is reported. This new ILSOS includes a new spacer for an IL support, a new tagging strategy, and fast, efficient and orthogonal removal of the ionic-liquid support, producing the N-linked core pentasaccharide with direct applicability potential in a short time, with high yield and on a large gram scale.

POLYMETHINE COMPOUNDS AND THEIR USE AS FLUORESCENT LABELS

The present disclosure relates to new compounds and their use as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

This study explores the possible use of reactive oxygen-activated DNA modifying agents against acute myeloid leukemia (AML). A key amine on the lead agent was investigated via cytotoxicity assays and was found necessary for potency. The two best compounds were screened via the NCI-60 cell panel. These two compounds had potency between 200 and 800 nM against many of the leukemia cancer cell types. Subsequent experiments explored activity against a transformed AML model that mimics the molecular signatures identified in primary AML patient samples. A lead compound had an IC50 of 760 nM against this AML cell line as well as a therapeutic index of 7.7 ± 3 between the transformed AML model cell line and non-cancerous human CD34+ blood stem/progenitor cells (UCB). The selectivity was much greater than the mainstays of AML treatment: doxorubicin and cytarabine. This manuscript demonstrates that this novel type of agent may be useful against AML.

ROS-Activated Compounds as Selective Anti-Cancer Therapeutics

Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.

LTA4H modulators and uses thereof

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation.

Studies towards the conception of new selective PPARβ/δ ligands

In order to define new PPARβ/δ ligands, SAR study on the selective PPARβ/δ activator L-165,041 led to the identification of one key functional group for selective PPARβ/δ activation. Furthermore, taking advantage of SAR studies done elsewhere on the most selective PPARβ/δ ligand GW501516, the conception of new ligands showing good affinity for PPARβ/δ is reported. Finally, synthesis and biological evaluation of pyridine analogues have shown the benefical effect of the pyridine ring on the PPARβ/δ subtype selectivity.

Phenyl and pyridyl LTA4H modulators

Leukotriene A4 hydrolase (LTA4H) inhibitors, compositions containing them, and methods of use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and inflammatory conditions.

BENZIMIDAZOLE, BENZTHIAZOLE AND BENZOXAZOLE DERIVATIVES AND THEIR USE AS LTA4H MODULATORS

Leukotriene A4 hydrolase (LTA4H) inhibitors of formula I, compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation, wherein X is selected from the group consisting of NR5, O, and S, with R5 being one of the H and CH3; Y is selected from the group consisting of CH2 and O; R4 is selected from the group consisting of H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3.

Arylenedioxy-bis-diketones

Phenylenedioxy-bis-dikeones having the formula STR1 useful as antiviral agents, are prepared by etherification of dihydric phenols and alkylation of beta-dikeones.